Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Feb;52(2):218-228.
doi: 10.1007/s00535-016-1230-0. Epub 2016 Jun 29.

Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study

Junichi Shoda  1 , Atsushi Matsuda  2 , Takashi Shida  3 , Masakazu Yamamoto  4 , Masato Nagino  5 , Toshio Tsuyuguchi  6 , Takahiro Yasaka  7 , Susumu Tazuma  8 , Kazuhisa Uchiyama  9 , Michiaki Unno  10 , Nobuaki Ohkohchi  11 , Yasuni Nakanuma  12 , Atsushi Kuno  2 , Hisashi Narimatsu  2
Affiliations
Clinical Trial

Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study

Junichi Shoda et al. J Gastroenterol. 2017 Feb.

Abstract

Background: Wisteria floribunda agglutinin (WFA)-sialylated mucin core polypeptide 1 (MUC1) was investigated as a new glycoprotein marker for cholangiocarcinoma (CC) using glycoproteomics technologies. In this multicenter study, WFA-sialylated MUC1 levels in serum and bile samples were measured to determine their diagnostic capability in biliary tract carcinoma (BTC) and intrahepatic (Ih) CC.

Methods: The study included 244 patients with BTC, 59 patients with IhCC, 287 patients with benign biliary tract diseases, and 44 control subjects.

Results: Serum WFA-sialylated MUC1 levels were significantly higher in patients with either BTC or IhCC than in control subjects and those with benign biliary tract diseases. Patients with IhCC showed higher WFA-sialylated MUC1 levels than patients with tumors at other sites. No significant differences in WFA-sialylated MUC1 levels were found with regard to cancer stage or tissue type. Receiver operating characteristic curve analysis showed that WFA-sialylated MUC1 was superior to carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) for the diagnosis of benign biliary tract diseases, BTC, and IhCC, as well as for stage I and II carcinomas. Significantly higher levels of biliary WFA-sialylated MUC1 were observed in BTC/IhCC than in benign biliary tract diseases. The diagnostic capability of biliary WFA-sialylated MUC1 was also superior to that of CA19-9, and diagnostic sensitivity was higher than that of biliary cytology for BTC/IhCC.

Conclusions: WFA-sialylated MUC1 is a useful novel biomarker for BTC/IhCC. In the future, this measurement should be applied in the clinical setting.

Keywords: Biliary tract carcinoma; Biomarker; Glycoproteomics; Intrahepatic cholangiocarcinoma; Multicenter study.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest. Financial support This work was supported in part by a Grant-in-aid from the National Survey for Intractable Hepatobiliary Diseases from the Ministry of Health, Labour and Welfare, Japan, and a Grant-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (Nos. 24390323 and 15K10197).

Figures

Fig. 1
Fig. 1
Subgroup analysis of total patients with either biliary tract carcinoma (BTC) or intrahepatic (Ih) cholangiocarcinoma (CC), patients with benign biliary tract disease (BD), and control subjects (controls) in terms of the positivity of WFA-sialylated MUC1 (WFA-MUC1) and CA19-9 in serum samples (upper panel) and bile samples (lower panel)
Fig. 2
Fig. 2
Comparison of the diagnostic power of biliary cytology, WFA-sialylated MUC1 (WFA-MUC1), and CA19-9 among all patients with biliary tract carcinoma or intrahepatic cholangiocarcinoma (CC), patients with perihilar CC or intrahepatic CC, those with distal CC, and those with gallbladder carcinoma
Fig. 3
Fig. 3
Pathological findings and positivity of WFA-sialylated MUC1 (WFA-MUC1), CA19-9, and CEA in serum samples (upper panels) and bile samples (lower panels) for all patients with either biliary tract carcinoma or intrahepatic cholangiocarcinoma
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0. Lyon: IARC Press; 2004.
    1. Altekruse SF, Petrick JL, Rolin AI, et al. Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States. PLoS one. 2015;10:e0120574. doi: 10.1371/journal.pone.0120574. - DOI - PMC - PubMed
    1. Division of Vital Statistics, Statistics and Information Department, Minister’s Secretariat, Ministry of Health, Labour and Welfare (MHLW): http://www.mhlw.go.jp/toukei/saikin/index.html.
    1. Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet. 2005;366:1303–1314. doi: 10.1016/S0140-6736(05)67530-7. - DOI - PubMed
    1. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40:472–477. doi: 10.1016/j.jhep.2003.11.030. - DOI - PubMed

MeSH terms